D&O Ongoing Disclosure – Paul Dalla Lana

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Vital Healthcare Property Trust
Date this disclosure made:
30-Aug-18
Date of last disclosure:
23-Aug-17
Director or senior manager giving disclosure
Full name(s):
Paul Dalla Lana
Name of listed issuer:
Vital Healthcare Property Trust
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Director of NorthWest Healthcare
Properties Management Limited
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary units in Vital Healthcare
Property Trust
Nature of the affected relevant interest(s):
Paul Dalla Lana has a relevant
interest in ordinary units held by
(a) NWI NZ Management
Company Limited (beneficial
owner) and (b) NWI Healthcare
Properties LP (beneficial owner),
as a result of each of those
entities being wholly owned
subsidiaries of NorthWest
Healthcare Properties REIT, of
which Paul Dalla Lana is the
Chairman of the Board of Trustees
and holds an approximate 25%
interest in.
For that relevant interest-
Number held in class before acquisition or disposal:
108,417,355
Number held in class after acquisition or disposal:
110,823,292
Current registered holder(s):
Deutsche Securities Australia
Limited (105,977,178) and Forsyth
Barr Custodians Limited
(2,440,157)
Registered holder(s) once transfers are registered:
Deutsche Securities Australia
Limited (105,977,178) and Forsyth
Barr Custodians Limited
(4,846,114)
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A
Details of affected derivative-
N/A
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative(if any):
N/A
The price specified in the terms of the derivative (if any):
N/A

Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative,-
N/A
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
Date of transaction:30-Aug-18
Nature of transaction:
Transaction one:
6,505,957 ordinary units were
issued to NorthWest Healthcare
Properties Management Limited,
manager of Vital Healthcare
Property Trust, as consideration
for the manager's incentive fee in
accordance with clauses 22.2(b)
and 22.3(b) of the Trust Deed.
Transaction two: immediately upon
the issue of units under
transaction one, 4,100,000 units
were transferred to Craigs
Investment Partners Limited on
behalf of certain of its third party
clients.
Transactions one and two
completed simulatenously such
that the 4,100,000 units
transferred pursuant to transaction
two were, in fact, issued directly to
Craigs Investment Partners
Limited and were never held by
NorthWest Healthcare Properties
Management Limited.
Name of any other party or parties to the transaction (if known):
Craigs Investment Partners
Limited & Forsyth Barr Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
The 6,505,957 units were issued
as consideration for NorthWest
Healthcare Properties
Management Limited's
management incentive fee in
accordance with clauses 22.2(b)
and 22.3(b) of the Trust Deed.
The consideration received for the
contemporaneous disposal of
4,100,000 units was $2.055 per
unit.
Number of financial products to which the transaction related:
Transaction one: 6,505,957
Transaction two: (4,100,000)
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
N/A
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:ordinary units

Nature of relevant interest:
Paul Dalla Lana has a relevant
interest in:
(a) 102,684,228 ordinary units
held by NWI Healthcare Properties
LP (as beneficial owner); and
(b) 8,139,064 ordinary units held
by NWI NZ Management
Company Limited (as beneficial
owner).
For that relevant interest,-
Number held in class:110,823,292
Current registered holder(s):
Deutsche Securities Australia
Limited (105,977,178) and Forsyth
Barr Custodians Limited
(4,846,114)
For a derivative relevant interest,-
Type of derivative:N/A
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative (if any):
N/A
The price's specified terms (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative relevant interest,-
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
N/A
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
September 3, 2018